Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Selective leukemic-cell killing by a novel functional class of thalidomide analogs.

Selective leukemic-cell killing by a novel functional class of thalidomide analogs. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Selective leukemic-cell killing by a novel functional class of thalidomide analogs. Abstract Text:

    yun geYun Ge,idalia montanoIdalia Montano,gabriella rusticiGabriella Rustici,wendy j freebernWendy J Freebern,cynthia m haggertyCynthia M Haggerty,wenwu cuiWenwu Cui,damaris ponciano-jacksonDamaris Ponciano-Jackson,g v r chandramouliG V R Chandramouli,erin r gardnerErin R Gardner,william d figgWilliam D Figg,mones abu-asabMones Abu-Asab,maria tsokosMaria Tsokos,sharon h jacksonSharon H Jackson,kevin gardnerKevin Gardner,

    Using a novel cell-based assay to profile transcriptional pathway targeting, we have identified a new functional class of thalidomide analogs with distinct and selective antileukemic activity. These agents activate nuclear factor of activated T cells (NFAT) transcriptional pathways while simultaneously repressing nuclear factor-kappaB (NF-kappaB) via a rapid intracellular amplification of reactive oxygen species (ROS). The elevated ROS is associated with increased intracellular free calcium, rapid dissipation of the mitochondrial membrane potential, disrupted mitochondrial structure, and caspase-independent cell death. This cytotoxicity is highly selective for transformed lymphoid cells, is reversed by free radical scavengers, synergizes with the antileukemic activity of other redox-directed compounds, and preferentially targets cells in the S phase of the cell cycle. Live-cell imaging reveals a rapid drug-induced burst of ROS originating in the endoplasmic reticulum and associated mitochondria just prior to spreading throughout the cell. As members of a novel functional class of "redoxreactive" thalidomides, these compounds provide a new tool through which selective cellular properties of redox status and intracellular bioactivation can be leveraged by rational combinatorial therapeutic strategies and appropriate drug design to exploit cell-specific vulnerabilities for maximum drug efficacy.

    Selective leukemic-cell killing by a novel functional class of thalidomide analogs. Publishing Authors By Initials

    y geY Ge,i montanoI Montano,g rusticiG Rustici,wj freebernWJ Freebern,cm haggertyCM Haggerty,w cuiW Cui,d ponciano-jacksonD Ponciano-Jackson,gv chandramouliGV Chandramouli,er gardnerER Gardner,wd figgWD Figg,m abu-asabM Abu-Asab,m tsokosM Tsokos,sh jacksonSH Jackson,k gardnerK Gardner,

    For similar organic chemicals: carboxylic acids: acids, carbocyclic: phthalic acids: phthalimides: thalidomide research abstracts see: organic chemicals: carboxylic acids: acids, carbocyclic: phthalic acids: phthalimides: thalidomide research

    PUBMED ID PMID:

    MEDLINE DATE:

    Selective leukemic-cell killing by a novel functional class of thalidomide analogs. Journal Published:

    PUBLICATION TYPE: Research Support, N.I.H., Intr

    Journal: Blood

    VOLUME: 108

    Page Numbers: 4126-35

    Journal Abbreviation: Blood

    ISSN: 0006-4971

    DAY: 29

    MONTH: 08

    YEAR: 2006

    Selective leukemic-cell killing by a novel functional class of thalidomide analogs. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 7603509

    Selective leukemic-cell killing by a novel functional class of thalidomide analogs. Keywords Mesh Terms:

    KEYWORDS: Thalidomide

    MESH TERMS: therapeutic use

    Chemical & Substance for Abstract: Selective leukemic-cell killing by a novel functional class of thalidomide analogs. Information

    Substance Name: Thalidomide

    Registry Number: 50-35-1

    Grant and Affiliation Information for Selective leukemic-cell killing by a novel functional class of thalidomide analogs.

    AFFILIATION: The Advanced Technology Center, Laboratory of Receptor Biology and Gene Expression, National Cancer Institute, Bethesda, MD 20892-4605, USA.

    Country: United States

    United States Research PublicationUnited States Research Publication

    AGENCY: United States NCI

    GRANT: N01-CO-12400

    ACRONYM: CO

    MEDLINETA: Blood

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Selective leukemic-cell killing by a novel functional class of thalidomide analogs Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News